{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"groups":[{"description":"Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.\n\ntherapeutic allogeneic lymphocytes: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (DLI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Percentage of Patients Who Are Able to Receive at Least One DLI Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}